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Summary Several mutant genetic classes that cause
isolated methylmalonic acidurias (MMAuria) are
known based on biochemical, enzymatic and genetic
complementation analysis. The mut0 and mutj defects
result from deficiency of MMCoA mutase apoenzyme
which requires adenosyl-cobalamin (Ado-Cbl) as co-
enzyme. The cblA, cblB and the variant 2 form of cblD
complementation groups are linked to processes
unique to Ado-Cbl synthesis. The cblC, cblD and cblF
complementation groups are associated with defective
methyl-cobalamin synthesis as well. Mutations in the
genes associated with most of these defects have been
described. Recently a few patients have been described
with mild MMAuria associated with mutations of the
MMCoA epimerase gene or with neurological symp-
toms due to SUCL mutations. A comprehensive diag-
nostic approach involves investigations at the level of
metabolites, genetic complementation analysis and en-
zymatic studies, and finally mutation analysis. MMA
levels in urine range from 10–20 mmol/mol creatinine
in mild disturbances of MMA metabolism to over
20 000 mmol/mol creatinine in severe MMCoA mutase
deficiency, but show considerable overlap and are of
limited value for differential diagnosis. The underlying
defect in isolated MMAuria can be characterized in
cultured skin fibroblasts using several assays, e.g.
conversion of propionate to succinate, specific activity
of MMCoA, cobalamin adenosyltransferase assay,
cellular uptake of CN-[57Co] cobalamin and its con-
version to cobalamin coenzymes and complementation
analysis. The reliable characterization of patients with
isolated MMAuria pinpoints the correct gene for mu-
tation analysis. Reliable classification of these patients
is essential for ongoing and future prospective studies
on treatment and outcome.
Abbreviations
MMCoA Methylmalonyl-CoA
MMA methylmalonic acid
MMAuria methylmalonic aciduria
Me-Cbl methylcobalamin
Ado-Cbl adenosylcobalamin
Introduction
Methylmalonyl-CoA (MMCoA), the D-isomer, is a key
metabolite in the catabolism of propionate, which is
derived from the breakdown of four amino acids,
pyrimidines, odd-chain fatty acids and cholesterol side-
chains (Fig. 1). D-MMCoA is converted to succinyl-
CoA through its L form by the successive action of
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MMCoA racemase (epimerase) and MMCoA mutase.
The mutase enzyme requires adenosylcobalamin
(Ado-Cbl) as coenzyme so that the integrity of
methylmalonic acid (MMA) metabolism is inextricably
linked to vitamin B12 (cobalamin), its adequate intake
and correct uptake, transport and intracellular metabo-
lism. Deficiency of MMCoA mutase leads to elevated
levels of MMA in body fluids. In humans vitamin B12 is a
co-factor for one other enzyme, methionine synthase.
This enzyme requires methylcobalamin (Me-Cbl) for
activity. Deficiency of this enzyme results in accumula-
tion of homocysteine and occurs in isolation or com-
bined with MMCoA mutase deficiency in certain
genetic defects of intracellular cobalamin metabolism
as well as in nutritional deficiency or disturbed uptake
or transport of vitamin B12 (Rosenblatt and Fenton
2001; Suormala et al 2004). In the combined defects
(cblC, cblD and cblF) both MMA and homocysteine
will accumulate and these defects must be borne in
mind when characterizing methylmalonic aciduria.
Genetic disorders causing methylmalonic
aciduria (MMAuria)
Several distinct mutant genetic classes, based on
biochemical, enzymatic and genetic complementation
analysis are known (Table 1).
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cblD variant 2
cblA
cblB
ADP
Fig. 1 Metabolic interrelation-
ships of methylmalonic acid.
Epimerase, methylmalonyl CoA
epimerase (EC:5.1.99.1); mutase,
methylmalonyl-CoA mutase
(EC 5.4.99.2); AdoCbl,
adenosylcobalamin; Ligase,
succinate-CoA ligase
(EC 6.2.1.4); ADP, adenosine
diphosphate; ATP, adenosine
triphosphate; GDP, guanosine
diphosphate; GTP, guanosine
triphosphate
Table 1 Methylmalonic acidurias: complementation groups
Complementation group Impaired synthesis Primary defect Elevated metabolite
mut0/mutj Mutase apoenzyme MMCoA mutase MMA
cblA AdoCbl ? Mitochondrial Cbl import MMA
cblB AdoCbl ATP:cobalamin adenosyl-transferase MMA
cblD-Var2 AdoCbl ? Cytosolic Cbl transport MMA
cblC AdoCbl, MeCbl ? Cytosolic Cbl transport MMA, Hcy
cblD AdoCbl, MeCbl ? Cytosolic Cbl transport MMA, Hcy
cblF AdoCbl, MeCbl Lysosomal Cbl release MMA, Hcy
cblE MeCbl MS-reductase Hcy
cblG MeCbl Methionine synthase (MS) Hcy
cblD-Var1 MeCbl ? Cytosolic Cbl transport Hcy
MMCoA, methylmalonyl-coenzyme A; MMA, methylmalonic acid; Hcy, homocyst(e)ine; cbl, cobalamin; AdoCbl, adenosylcobala-
min; MeCbl, methylcobalamin; MS, methionine synthase
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The mut0 and mutj defects (OMIM 251000) belong
to a single genetic complementation class and result
from deficiency of MMCoA mutase apoenzyme due to
mutations of the MUT gene (Ledley et al 1988).
Differentiation of these defects is based on the
presence (mutj) or absence (mut0) of residual enzyme
activity in cultured fibroblasts and response to vitamin
B12 in vitro and in vivo. MMCoA mutase (MCM, EC
5.4.99.2) is a mitochondrial enzyme requiring 5¶-
deoxyadenosylcobalamin. The gene (MUT) maps to
6p21 and its full-length cDNA codes for a 750-amino-
acid protein of 88.2 kDa. The gene contains 13 exons
spanning more than 35 kb and so far approximately
200 mutations have been identified (Table 2). The
enzyme contains an N-terminal mitochondrial leader
sequence of 32 amino acids and the mature form is a
dimer of identical subunits of 78.5 kDa. Each subunit
contains two main functional domains, an N-terminal
(ba)8 barrel (residues 88–422) with the substrate
binding site and a C-terminal (ba)5 Ado-Cbl binding
domain (residues 578–750). The two domains are
connected by a long linking region (residues 423–577)
(Fenton et al 2001).
The cblA (OMIM 251100) and cblB (OMIM 251110)
complementation groups are linked to processes unique
to Ado-Cbl synthesis and cause isolated MMAuria.
Genes for the cblA (MMAA) and cblB (MMAB)
groups have recently been described (Dobson et al
2002a, b).
The MMAA gene is located at 4q31.1-q31.2 and
spans about 17.1 kb containing 7 exons, but exon 1 is
untranslated. The full-length cDNA codes for a 418-
amino-acid protein of 46.5 kDa. At least 28 mutations
have been identified in 37 cblA patients (Table 2). The
cblA protein contains an N-terminal mitochondrial
leader sequence and cleavage site as well as Walker A
and B ATP-binding motifs, a Mg2+-binding site and a
GTP-binding site, but its exact function is unclear. It
was first thought to be responsible for translocation of
cobalamin into mitochondria prior to the final steps of
AdoCbl synthesis (Dobson et al 2002a). More recent
evidence, however, points to a role of the protein in
the assembly and stabilization of holo-MMCoA-mu-
tase analogous to its bacterial homologue meaB. This
enzyme forms a complex with MMCoA mutase,
stimulates its activity and protects the enzyme from
irreversible inactivation (Padovani and Banerjee 2006).
The MMAB gene for cobalamin adenosyltransferase
(EC 2.5.1.17) maps to 12q24; it consists of 9 exons
extending over 18.87 kb and its full-length cDNA codes
for a 250-amino-acid protein (27.3 kDa) (Dobson et al
2002b). The cblB enzyme contains a leader sequence
and signal cleavage site consistent with localization to
the mitochondrion. At least 24 mutations associated
with low Ado-Cbl synthesis and mainly involving amino
acids from the active site have been found in patients in
the cblB complementation group.
Defective synthesis of both Ado-Cbl and Me-Cbl
occurs in the cblC, cblF and combined form of cblD
complementation groups as well as in nutritional
deficiency or disturbed uptake or transport of vitamin
B12 (for review see Whitehead 2006).
The gene associated with the cblC defect is MMACHC
which maps to chromosome 1p34.1; it comprises 5 exons
and its full length cDNA contains 846 base pairs
corresponding to a protein of 282 amino acids with a
molecular weight of 31.7 kDa (Lerner-Ellis et al. 2006b).
The protein appears to locate to the cytosol and homol-
ogy with bacterial cobalamin transport proteins suggests
a role in intracellular channelling of Cbl (Table 2).
The cblD complementation group (OMIM 277410)
was first associated with combined MMAuria and
homocystinuria, but it is now known that two addi-
tional variant forms of this mutant class exist with
either isolated homocystinuria (cblD-variant 1) or iso-
lated MMAuria (cblD-variant 2) (Coelho et al 2008;
Suormala et al 2004).
The previously described single patient (Watkins
et al. 2000) who was thought to belong to a new
complementation group (cblH Watkins et al 2000) also
belongs to the cblD-variant 2 mutant class.
The cblF defect is caused by defective release of Cbl
from lysosomes (Suormala et al 2004) and its gene has
not yet been identified.
Recently a few patients have been described with mild
MMAuria associated with a mutation of the MMCoA
epimerase gene (MCEE), but these patients had no
consistent clinical phenotype, as outlined below.
Diagnostic approach
A comprehensive diagnostic approach involves inves-
tigations at the level of metabolites, genetic comple-
mentation analysis and enzymatic studies, and finally
mutation analysis (Fig. 2).
Metabolites
The measurement of MMA and related metabolites
such as 3-hydroxypropionate and methylcitrate in
urine provides a reliable first-line diagnostic approach
in patients suspected to have a disorder of MMA
metabolism.
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In normal subjects MMA concentrations are age-
dependent with median values (P95 limits) of 1.1 (4.8)
mmol/mol creatinine below 30 days, 5.2 (49) mmol/mol
creatinine at 1–6 months, and 0.8 (6.5) mmol/mol
creatinine at 6–12 months of age (Boulat et al 2003).
Elevated levels range from the order of 10–20
mmol/mol creatinine in mild disturbances of MMA
metabolism to over 20 000 mmol/mol creatinine in
severe MMCoA mutase deficiency (Fig. 3) and can be
accompanied by increased levels of a range of related
metabolites such as methylcitrate, 3-hydroxypropio-
nate, lactate and propionylglycine.
Since several possible causes of elevated MMA are
known (Table 3), each must be carefully considered,
taking into account the clinical presentation and
nutritional state of the patient (Fig. 2).
Although concentrations of MMA are generally
higher in the genetic disorders than in absorption and
transport defects or nutritional vitamin B12deficiency,
there is considerable overlap. Thus the values them-
selves are of limited value in the differential diagnosis
because of this overlap (see Fig. 3).
In addition, several factors such as protein intake, the
catabolic state and associated metabolic decompensation,
renal function as well as vitamin B12 status can greatly
influence MMA levels, especially in urine. Also there
appears to be wide variation in MMA levels independent
of the changes in these factors. Furthermore, analytical
variation as shown by results within the ERNDIM EQA
scheme for organic acids can contribute to apparent varia-
tion in individual subjects (http://www.erndim.unibas.ch).
This variation makes comparison of concentrations
obtained in different laboratories of limited value.
Analytical improvements such as the use of GC-MS
stable-isotope dilution methods and participation of labo-
ratories in external QA will improve analytical variation.
Use of MMA levels in plasma (normal <0.27 mmol/L)
may well be a more reliable approach (Chandler et al
2007), but more evidence is needed.
CSF measurements of MMA (control values 0.19–
0.67 mmol/L) are generally not necessary for diagnostic
Elevated methylmalonic acid (MMA) in urine or plasma
Plasma total homocysteine (tHC)
Investigate
transport defects and 
transcobalamin deficiency º
MMAuria ± related metabolites* Nutritional history / serum B12
Loading test with
parenteral OH-Cbl
Nutritional B12
deficiency
Mutation analysis of specific gene
Propionate incorporation 
Methionine synthesis, enzymes 
Complementation analysis
Propionate incorporation ± OH-Cbl
Enzymes
Complementation analysis
normalelevated
normal
remains 
elevated
complete 
normalization
Repeat MMA and tHC
mild MMA elevation
+ encephalomyopathy
+ C4DC
consider “atypical”
MMAuria (SUCL) 
persistent
MMAuria
abnormal / 
low serum B12
Fig. 2 Diagnostic flowchart.
*Related metabolites such as
methylcitrate, 3-hydroxypropionate,
lactate and propionylglycine.
-For further details see Whitehead
(2006). C4DC, succinyl- or
methymalonylcarnitine
>10'000
5'000
1'000
100
Mutº
cblB
MCEE
Benign 
MMA
Cbl A 
mut-
SUCLG1
Vit B12
def
Cbl
C/D/F
SUCLA2
mmol/mol creat.
Fig. 3 Urinary MMA levels in various types of disorders. The
levels shown are approximations based on ranges of values
reported in the literature. Note the arbitrary nonlinear scale.
Complementation groups, mut0, mutj, cblA, cblB, cblC, cblD,
cblF. MCEE, methylmalonyl-CoA epimerase deficiency; MMA,
methylmalonic acid; SUCLG1, succinate-CoA ligase, alpha
subunit; SUCLA2, succinate-CoA ligase, ADP-forming beta
subunit
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purposes although this may be useful in the investiga-
tion of atypical forms, especially in those with mainly
neurological involvement (Mayatepek et al 1996).
Increasingly, measurement of acyl carnitine esters in
dried blood spots is being applied to diagnosis of the
MMAurias, in particular in extended newborn screen-
ing programmes (Schulze et al 2003; Wilcken et al
2003). Note, however, that MMAuria is not included
in all such schemes as, for example, in Germany
(discontinued in 2005).
It is likely that in future, as more and more
laboratories undertake metabolic screening and also
newborn screening by acylcarnitine measurements, a
more common marker of MMA metabolism will be
C4-dicarboxylic acylcarnitine (C4DC) but this can be
either methylmalonyl- or succinylcarnitine.
Plasma total homocysteine measurement (Fowler
and Jakobs 1998) is essential in the differential diag-
nosis of elevated MMA levels of all degree to exclude
combined forms of disorders of intracellular cobalamin
metabolism as well as transport defects and nutritional
causes (Fig. 2).
Testing of the response to vitamin B12
Defects of the translocation and intracellular synthesis
of the active cofactors of vitamin B12 often respond to
pharmacological doses of the vitamin with clinical and
biochemical improvement. CblC and cblD defects are
routinely treated with hydroxocobalamin but not all
patients with defects of synthesis of adenosylcobalamin
(cblA and cblB) will respond. While most patients with
cblA will improve, only about one-third of cblB
patients will do so (Matsui et al 1983). This response
was first noted in a patient reported by Rosenberg and
his colleagues (Rosenberg et al 1968) and since then
many responsive patients have been identified. Some
patients in the mut complementation group will also
respond, particularly mutj (Ho¨rster et al 2007). Mut0
patients have also been reported to have responded to
parenteral vitamin B12 (Matsui et al 1983), but a genu-
ine response is rare.
The difficulty in interpreting previous reports is that
the testing with vitamin B12 has never been standardized
and what constitutes a response never clearly defined. In
a survey of European centres there was a very marked
variation in practice (Zwicker et al 2008). Vitamin B12
was given as hydroxocobalamin intramuscularly or
intravenously or as cyanocobalamin intramuscularly.
The response was assessed by changes in plasma or urine
methylmalonate or in blood spot propionylcarnitine.
One to three specimens were collected before giving
the vitamin and 1–7 specimens afterwards. The response
was judged by a fall in metabolite concentration of
between 10% and 90% or by a fall in methylmalonate
to a value below 1000 mmol/mol creatinine. Clearly,
using some of these criteria makes it doubtful that there
was a genuine response and such variation in practice
makes it impossible to make any comparisons.
A standardized test is proposed. The purpose of this
test is to identify those patients who genuinely benefit
from vitamin B12. It is important to remember that no
child should be given unnecessary or ineffective
treatment, particularly by injection.
Parallel to this test the enzymology including
in vitro response to adenosylcobalamin and if possible
the complementation group should be determined (see
below). The vitamin B12 test should not be delayed by
waiting for the results of these tests.
1. The patient should be clinically stable on the same
treatment for at least one month. The protein and
energy intake should be specified.
2. If the patient is already receiving cobalamin, this
should be stopped for at least one month before
the test. If the patient appears to deteriorate,
restart vitamin B12 and defer the test. Note: As a
general rule patients with MMA excretion greater
than 10 000 mmol/mol creatinine and those who are
clinically unstable rarely respond to vitamin B12.
3. Baseline urine collections. At least three speci-
mens should be collected on different days. Plasma
Table 3 Causes of elevated MMA in plasma and urine
Non-genetic
Nutritional deficiency
Subjects on strict vegetarian diet/vegans
(Breastfed) babies of vegan mothers or mothers with
unrecognized disturbed vitamin B12 metabolism
Reduced intestinal absorption (elderly persons)
Genetic disorders
Disorders of MMA-CoA conversion
Methlylmalonyl-CoA mutase
Methlylmalonyl-CoA epimerase (racemase)
Disorders of absorption and transport of cobalamin
Hereditary intrinsic factor deficiency
Defective transport of Cbl by enterocytes
(Imerslund–Gra¨sbeck syndrome)
Haptocorrin (R Binder) deficiency
Transcobalamin (TC) Deficiency
Disorders of intracellular utilization of Cbl
Combined deficiencies of AdoCbl and MeCbl
AdoCbl deficiency
Atypical MMAurias associated with encephalomyopathy
SUCLG1, succinate-CoA ligase, alpha subunit
SUCLA2, succinate-CoA ligase, ADP-forming beta subunit
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concentrations may be used only if a sensitive
assay (stable-isotope dilution assay) is available.
4. Give hydroxocobalamin 1 mg intramuscularly on
three consecutive days.
5. After the cobalamin injection, collect urine (or
plasma) specimens on alternate days for 10 days.
6. The urine or plasma samples should be analysed in
the same run in a laboratory participating in a
recognized quality control scheme for methylma-
lonic acid using GCMS.
7. A decrease of the mean urine or plasma MMA
concentrations of more than 50% should be
regarded as indicative of a beneficial response.
Enzymatic and complementation analysis
Once nutritional causes have been excluded, the
complexity of causes of inherited isolated MMAuria
necessitates characterization of the underlying defect
in cultured skin fibroblasts using several assays.
The overall conversion of propionate to succinate is
determined by the incorporation of label from
[14C]propionate into cell proteins (Willard et al 1976)
(Fig. 4). Specific activity of MMCoA mutase can be
measured using a radioactive substrate in the presence
and absence of Ado-Cbl (Baumgartner 1983) (Fig. 5).
Distinction of isolated MMAurias into mut0 or
mutj is based on the somewhat arbitrary biochemical
assessment of in vitro response to hydroxocobalamin.
Mut0 is defined as very low mutase activity together
with a ratio of propionate incorporation with or
without supplemented hydroxocobalamin lower than
1.5 which is the upper limit found in control cell lines.
Mutj is defined as low to moderate residual mutase
activity and a ratio of >1.5 although it must be borne in
mind that in our series some cell lines showed
borderline values of 1.2–1.7 and assays needed to be
repeated several times to enable definite classification
(Lempp et al 2007).
Cobalamin adenosyltransferase can be measured by
monitoring the conversion of OH-[57Co]cobalamin to
Ado-Cbl. The reaction must be performed in the dark
and under hydrogen to provide reducing conditions
(Fenton and Rosenberg 1981).
The cellular uptake of CN-[57Co]cobalamin and its
conversion to cobalamin coenzymes can be measured
in intact fibroblasts in monolayer culture. Human
serum is used as a source of transcobalamin to
facilitate cellular uptake (Fowler and Jakobs 1998).
Complementation analysis is performed by measuring
the incorporation of [14C]propionate into protein in
patient cells mixed with cells of known complementation
groups and treated with 40% polyethyleneglycol (PEG)
which results in the formation of multinuclear cells
(Fig. 6) (Zavadakova et al 2002).
In the investigation of combined MMAuria and
homocystinuria the function of methionine synthase
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Fig. 4 Propionate incorporation assay in 66 mut0 and 17 mutj
cell lines. Intact fibroblasts in monolayer culture are incubated
with [14C]propionate (0.2 mmol/L) in medium containing 15%
serum for 16 h at 37-C. Then cells are harvested with trypsin
followed by precipitation of protein with 5% trichloroacetic acid.
Protein is solubilized in 1 mol/L NaOH . The protein concentra-
tion is determined by Lowry and radioactivity is measured by
scintillation counting. Activity is expressed as pmol propionate
fixed per mg protein per 16 h. Shaded bars represent the ranges
with median values depicted by solid bars. MEM;= fibroblasts
grown in minimal essential medium without added hydroxoco-
balamin. MEM+ = fibroblasts grown in medium with 10 mg/L
added hydroxocobalamin
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can be determined by measurement of conversion of
[14C]formate to methionine in intact fibroblasts in
monolayer culture (Fowler et al 1997).
The results of these assays, the most important
being the determination of propionate incorporation
and MMCoA mutase activity in fibroblasts grown in
medium with and without supplemented hydroxoco-
balamin, allow the reliable characterization of patients
with isolated MMAuria and identify the correct gene
for mutation analysis (Table 4).
Mutation analysis
Many different complementation classes exist and
these cannot be distinguished by clinical presentation
and/or response to high-dose parenteral vitamin B12
administration. Enzymatic and/or complementation
analysis is necessary before proceeding to mutation
analysis of single genes (Fig. 2). Table 2 summarizes
present knowledge on genes and mutations relevant to
isolated MMAuria.
Approaching 200 mutations of the MUT gene have
been described in MMCoA mutase deficient patients
(Lempp et al 2007; Worgan et al 2006). Most are
private, although a few occur in between 10% and 20%
of mutant alleles. The p.R694W mutation is associated
with the mutj form (Lempp et al 2007). Two others
have been identified in particular ethnic groups with a
relatively high frequency (Worgan et al 2006).
In the cblA defect the p.R145X mutation was found
to be present in 43% of mutant alleles and was associ-
ated with a common haplotype (Lerner-Ellis et al 2004).
The p.R186W mutation of the MMAB gene
accounted for 33% of mutant alleles in cblB patients
who were of European origin and presented with a
severe clinical phenotype (Lerner-Ellis et al 2006a).
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Fig. 5 Methylmalonyl-CoA mutase assay. Fibroblast extract is
incubated with [14C]MMCoA (4 mmol/L) at pH 7.4, 37-C for
60 min, without (holomutase) and +50 mmol/L AdoCbl (total
mutase). Free [14C]succinic acid is released by alkaline hydrolysis,
unlabelled succinic acid is added as carrier and is separated by anion
exchange HPLC. Fractions are collected and counted for radioac-
tivity. Activity is expressed as pmol succinate formed per minute per
mg extract protein. Shaded bars represent the ranges, with median
values depicted by solid bars. MEM;=fibroblasts grown in
minimal essential medium without added hydroxocobalamin.
MEM+ = fibroblasts grown in medium with 10 mg/L added
hydroxocobalamin
Fig. 6 Complementation analysis of cblD-variant 2 cell line.
Fibroblasts of a particular patient were mixed with fibroblasts
belonging to known complementation groups, fused with poly-
ethyleneglycol 1500 (PEG) treatment (shaded columns), and 3
days later propionate incorporation was measured. Parallel
cultures of mixed unfused cells were used as background
controls (unshaded columns). Self-fusions were used as a
negative control
J Inherit Metab Dis (2008) 31:350–360 357
Mutations of the recently identified gene responsible
for the cblD defect (MMADHC) have been described in
four subjects with combined MMAuria and homocysti-
nuria and in four subjects with the isolated MMAuria
form of this defect (Coelho et al 2008).
At least 44 mutations have been described in the
MMACHC gene responsible for the cblC defect
(Lerner-Ellis et al 2006b, Nogueira et al 2008). The
c.271dupA mutation occurred in about 40% of alleles
and correlated with early-onset disease. In addition, two
nonsense mutations, R111X and R132X, were found in
10–20% of mutant alleles. Interestingly, one of these
(R132X) was associated with late-onset disease.
Miscellaneous disorders with mildly elevated MMA
MCoA epimerase deficiency
Mutations of the gene (MCEE) coding for this enzyme
deficiency have been reported in six patients. The first
patient with MMA levels of 142–300 mmol/mol
creatinine and increased propionylcarnitine (Bikker
et al 2006) was also affected by sepiapterin reductase
deficiency with a clinical phenotype reminiscent of that
disorder. Dobson and colleagues (2006) reported a
child previously thought to have MMA due to the
cblA defect who presented at 13.5 months with severe
metabolic acidosis requiring intensive care, having pre-
viously failed to thrive. MMA and methylcitrate were
elevated in urine and plasma MMA was 11.1 mmol/L
(normal <0.27). Urine MMA while on a normal
protein intake with oral cobalamin was 180–1456
mmol/mol creatinine. Growth and mental develop-
ment are normal. An older sister showed MMA levels
of 95–166 mmol/mol creatinine on a self restricted
low-protein intake but has remained asymptomatic.
It is likely that this enzyme deficiency leads to only
a partial block in MMCoA catabolism owing to the
ability of D-MMCoA to interconvert with L-MMCoA
through deacetylation and acetylation of free MMA
(Fig. 1). This is reflected in the relatively modest eleva-
tion of urine MMA as well as the only partially reduced
levels of propionate incorporation into macromolecules
in cultured fibroblasts. Gradinger and colleagues (2007)
reported pathogenic mutations in 5 of 229 patients
with unexplained MMAuria but there was no consis-
tent clinical phenotype. Three of these five patients
had two mutant alleles but propionate incorporation
was decreased in only two. The other two subjects
were only heterozygous for a single MCEE mutation
and normal propionate incorporation was found in
their cultured fibroblasts.
Thus conclusions on the clinical consequences of
MMACoA epimerase deficiency cannot be made.
Atypical MMA with neurological symptoms
due to SUCL mutations
The succinate-CoA ligase (SUCL) enzyme complex
catalyses the conversion of succinyl-CoA to succinate
in the tricarboxylic acid cycle (Fig. 1). Two forms of
the complex exist, each comprising a common alpha
unit and one of two different beta subunits which
impose specificity for either GDP or ADP in the
reaction. Mutations of the ADP-forming beta subunit
SUCLA2 are associated with depletion of mitochon-
drial DNA (Elpeleg et al. 2005) and deficiency of
complexes I, III and IV of the respiratory chain.
Further reported patients (Carrozzo et al. 2007;
Ostergaard et al. 2007a) characterized by Leigh-like
encephalomyopathy, dystonia and deafness have been
shown to excrete mildly elevated levels of MMA. The
mild MMAuria ranged from 16 to 212 mmol/mol cre-
Table 4 Methylmalonic acidurias: findings in fibroblast assays (N = normal)
Medium OHCbl Propionate incorporation MMA-CoA mutase CN-[57Co]Cbl uptake
jAdoCbl +AdoCbl Total AdoCbl MeCbl
mut0 j , T, , N N N
+ , , ,
mutj j , T, , N TN N
+ upto N , TN
cblA j , T, N N , N
+ N T, N
cblB j , T, N N , N
+ , or N , N
cblD-var2 j , T, N N , N
+ N , N
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atinine and is accompanied by a range of increased
metabolites such as methylcitrate, 3-hydroxypropionate,
propionylcarnitine, MMA, methylmalonylcarnitine,
succinylcarnitine, lactate, citrate and succinate. Thus
MMA is likely to constitute a marker for the disease
rather than to be responsible for the phenotype.
Fatal lactic acidosis of neonatal onset with mtDNA
depletion was recently described in two patients with
mutations in the alpha subunit, SUCLG1 (Ostergaard
et al. 2007b) with mildly increased urinary MMA
(68 mmol/mol creatinine) in one of them.
Further cases, some of which have been reported
previously (Yano et al. 2003) presented with a milder
phenotype including developmental delay, generalized
muscular hypotonia and bilateral papillary oedema but
without deafness (A. Burlina, C. Dionisi-Vici and R.
Wevers, personal communication 2007). One of them
showed increased urinary MMA (285 mmol/mol cre-
atinine) and related organic acids and elevated pro-
pionylcarnitine and methylmalonylcarnitine (Yano
et al 2003; patient 1).
In conclusion, several possible causes of elevated
MMA are known (Table 3) and each must be carefully
considered in relation to the clinical presentation and
nutritional state of the patient. The diagnostic ap-
proach and methods described here allow a definitive
classification of this heterogeneous group of disorders.
It must be emphasized that such investigations need to
be performed in laboratories with comprehensive
experience. Reliable classification of these patients is
essential for ongoing and future prospective studies on
treatment and outcome.
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